Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "Score"

848 News Found

Lupin receives EIR from USFDA for its Somerset manufacturing facility
Drug Approval | February 21, 2025

Lupin receives EIR from USFDA for its Somerset manufacturing facility

the inspection conducted from January 27 to January 31, 2025


Orchid Pharma's Alathur API facility successfully completes USFDA inspection
Drug Approval | February 20, 2025

Orchid Pharma's Alathur API facility successfully completes USFDA inspection

The Alathur facility specializes in the production of Cephalosporin antibiotics


Lupin receives “A-” leadership rating from CDP in climate change and water security
Sustainability | February 19, 2025

Lupin receives “A-” leadership rating from CDP in climate change and water security

This rating reflects Lupin's leadership in environmental transparency and performance


Nectar Life Care launches affordable anti-diabetic range of medicines
News | February 17, 2025

Nectar Life Care launches affordable anti-diabetic range of medicines

Offers affordable, high-quality solutions for diabetes care


Tata Chemicals signs MoU with BSDT’s Integrated Cancer Treatment and Research Centre, Pune
Healthcare | February 07, 2025

Tata Chemicals signs MoU with BSDT’s Integrated Cancer Treatment and Research Centre, Pune

This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being


India reaffirms commitment to global pharmaceutical standardization and regulatory convergence: Anupriya Patel
Policy | February 06, 2025

India reaffirms commitment to global pharmaceutical standardization and regulatory convergence: Anupriya Patel

International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization


Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
News | February 04, 2025

Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr

Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin


Roche receives FDA approval for the first companion diagnostic to identify patients ultralow metastatic breast cancer
Drug Approval | February 01, 2025

Roche receives FDA approval for the first companion diagnostic to identify patients ultralow metastatic breast cancer

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.


Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines
Policy | February 01, 2025

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25